Teleflex Stock News

The Global Medical Needles Market report offers a comprehensive evaluation of the market. It does give in-depth analysis via qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven

TheStreet cut shares of Teleflex (NYSE:TFX) from a b rating to a c+ rating in a research note published on Wednesday morning, TheStreetRatingsTable reports. Several other analysts also recently weighed in on the company. Raymond James lowered their price objective on Teleflex from $440.00 to $391.00 and set an outperform rating for the company in []

Ellevest Inc. increased its stake in shares of Teleflex Incorporated (NYSE:TFX) by 86.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 307 shares of the medical technology company’s stock after buying an additional 142 shares during the quarter. Ellevest Inc.’s […]

LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Huge end-of-the-year sale with discounts on ALL market research reports at The Business Research Company! Grab your deal now. According to The Business Research Company''s research report on the voice prosthesis market, the global voice prosthesis devices and equipment market is highly fragmented, with a few players dominating the market. The top ten competitors in the market made up to 76.21% of the total market in 2020. Major players in the market include Smiths Medical, Teleflex Incorporated, Atos Medical, Servona GmbH, Andreas Fahl MedizintechnikVertrieb and others. Voice prosthesis devices and equipment manufacturers are focusing on strategic acquisitions to expand into newer markets, and to increase their market share. An acquisition refers to the process under which a company purchases the majority of another company''s shares to gain control over the company. The advantages of acquisitions include expansion to newer markets, access to newer technologies, and increased revenues.

Frontier Capital Management Co. LLC reduced its stake in shares of Teleflex Incorporated (NYSE:TFX) by 7.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 134,314 shares of the medical technology companys stock after selling 10,654 shares during the period. Frontier []

Overview Intravenous access devices allow repeated and long-term access to the bloodstream for frequent or regular administration of drugs, like intravenous (IV) antibiotics. Market Statistics The global intravenous access devices market was valued at US$ 39,834.8 million in 2019

The stock price of Teleflex, best known for its single-use medical devices for common diagnostic and therapeutic procedures, has seen a decline of 12% over the last month, while it was down over 4% la

Stents can be used for similar reasons in the trachea, especially to maintain lumen patency to prevent death. Stenting in the tracheobronchial tree is usually used as a last resort for severe conditions such as recurrent carcinoma and severe tracheal

Teleflex Incorporated (TFX) shares closed today at 1.4% above its 52 week low of $304.57, giving the company a market cap of $14B. The stock is currently down 25.6% year-to-date, down 17.5% over the past 12 months, and up 108.2% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 29.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -284.0% The company's stock price performance over the past 12 months lags the peer average by -173.8% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 645.6% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Teleflex Incorporated (NYSE:TFX) shares, rose in value on Friday, 11/26/21, with the stock price down by -3.97% to the previous days close as strong demand from buyers drove the stock to $305.15. Actively observing the price movement in the last trading, the stock closed the session at $317.77, falling within a range of $304.57 and Is Teleflex Incorporated (NYSE: TFX) A Good Pick For New Investors Now? Read More »

WAYNE, Pa., Nov. 26, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced a worldwide recall of Arrow-Trerotola Over-The-Wire PTD® Kit Percutaneous Thrombolytic Device: 7FR. The Arrow-Trerotola Percutaneous Thrombolytic Device (PTD) Catheter, in conjunction with the Arrow Rotator Drive Unit, permits mechanical declotting of native arterio-venous (AV) fistulae and synthetic dialysis grafts.

Wall Street analysts expect Teleflex Incorporated (NYSE:TFX) to announce $750.89 million in sales for the current quarter, Zacks reports. Ten analysts have provided estimates for Teleflexs earnings. The lowest sales estimate is $741.95 million and the highest is $765.88 million. Teleflex reported sales of $711.18 million in the same quarter last year, which indicates a []

Stem cell concentration system further helps to obtain viability and proliferative potential of stem cell expected to gaining more traction and drive the stem cell concentration system market. The Global Stem Cell Concentration System Market Report provides planned insights into the

Teleflex Incorporated (TFX) shares closed today at 1.6% above its 52 week low of $312.68, giving the company a market cap of $14B. The stock is currently down 23.1% year-to-date, down 15.2% over the past 12 months, and up 113.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.2%. Trading Activity Trading volume this week was 28.8% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -233.8% The company's stock price performance over the past 12 months lags the peer average by -147.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 765.4% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Anesthesia Video Laryngoscope market research report serves a lot of parameters and detailed data about healthcare industry. The report endows with the steadfast knowledge and information of revolutionizing market landscape, what already exists in the market, future trends or what